Previous studies have shown that metabolic information provided by 3D Magnetic Resonance Spectroscopy Imaging (MRSI) could affect the definition of target volumes for radiation treatments (RT). This study aimed to (i) investigate the effect of incorporating spectroscopic volumes as determined by MRSI on target volume definition, patient selection eligibility, and dose prescription for stereotactic radiosurgery treatment planning; (ii) correlate the spatial extent of pre-SRS spectroscopic abnormality and treatment volumes with areas of focal recurrence as defined by changes in contrast enhancement; and (iii) examine the metabolic changes following SRS to assess treatment response. Twenty-six patients treated with Gamma Knife radiosurgery for recurrent glioblastoma multiforme (GBM) were retrospectively evaluated. All patients underwent both MRI and MRSI studies prior to SRS.
Introduction
Malignant gliomas make up approximately 35% to 45% of all primary brain tumors, of which 85% are Glioblastoma Multiforme (GBM), the most malignant type of brain tumor (1). The prognosis of GBM treated with surgery and radiation therapy remains dismal, with a median survival of typically 9-12 months (2, 3), and a median of 15 months with the incorporation of temozolomide (4).
The current standard of care for patients with GBM consists of maximal resection followed by concurrent radiation therapy (RT) and chemotherapy with Te-Technology in Cancer Research & Treatment, Volume 6, Number 5, October 2007 mozolomide, then followed by adjuvant chemotherapy with Temozolomide for six months (2, 4) . However, most patients with GBM recur locally quite rapidly, with 80% of recurrences located within 2 cm of the enhancing extent of the original tumor site (3). RTOG 93-05 sought to explore the value of radiosurgery delivered as an upfront boost in patients following surgical resection of a GBM in the hopes to increase local control and overall outcome (5). However, RS in conjunction with external beam RT and BCNU did not prove efficacious in the primary treatment setting when compared to RT and BCNU alone (median survival 13.5 months vs. 13.6 months, respectively). Treatment options at the time of recurrence include re-operation, chemotherapy, or focal RT, depending on prior treatment history (3). Gamma Knife or Linac-based stereotactic radiosurgery delivers a high dose of radiation to a locally confined target while sparing surrounding tissue. Radiosurgical target volumes are customarily delineated based on contrast-enhanced T1-weighted MRI to include the contrast-enhancing region only. Recent studies (6, 7) utilizing Magnetic Resonance Spectroscopy Imaging (MRSI) have suggested that contrast enhancement (CE) is not always an entirely reliable indicator of tumor recurrence because it could also reflect or partially contain areas of necrosis. In addition, tumor-suggestive metabolism is often seen beyond the region of compromised blood-brain barrier (reflected by extent of CE) and would be left untreated with the described conventional tumor target definition. To gain the most benefit from radiosurgery's ability to deliver conformal dose distributions, it is critical that the target volume is identified and defined as accurately as possible.
One way to improve the accuracy of tumor definition is to utilize metabolic information in conjunction with MRI or other conventional imaging modalities to define the target volume. Potentially useful metabolic imaging techniques for brain tumors include Positron emission tomography (PET) or Single photon emission computed tomography (SPECT) employing amino acid radionuclides such as C11-methionine (MET-PET) or I123-methyl-Tyrosine (IMT-SPECT), and to merge the derived metabolic information with CT/ MR for tumor definition (8-10).
Another option is to use three-dimensional Proton ( 1 H) magnetic resonance spectroscopy imaging (MRSI). MRSI is a noninvasive in vivo technique that provides biochemical and functional measures of brain tissue, and allows differentiation of normal brain from tumor tissue based on metabolic levels of Choline (Cho), Creatine (Cre), N-acetylaspartate (NAA), and Lactate/Lipid (LL). Cho is a neurotransmitter, indicative of cell membrane synthesis and degradation and is usually increased in tumor; Cr is an indicator of cellular bioenergetic processes; NAA is a neuronal marker absent in glial cells and is typically decreased or absent in tumors due to diminished or loss of neuronal function; Lactate is an end-product of an-aerobic oxidation while lipid, typically co-located with lactate, reflects cellular breakdown and necrosis. Studies have shown that gliomas exhibit a markedly high resonance of Cho and/or a low NAA (11), and studies conducted at our institution have correlated these spectral findings with positive tumor biopsy samples obtained through image guidance (12).
Previous retrospective analyses of radiosurgery patients treated at our institution have suggested that MRSI may play an important role in the SRS treatment planning process by providing better tissue discrimination between normal brain and glioma tissue, and for the purpose of target definition in general (13-16). Graves et al. (13) have shown that patients with metabolic abnormalities extending outside the conventionally defined radiosurgical target exhibited significantly increased volumes of CE during follow-up, significantly shorter time to further treatment, and significantly shorter survival when compared to patients in whom metabolic abnormalities resided primarily within the SRS target volumes. An updated report by Chan et al. (14) confirmed these findings on a lesser significant scale, possibly reflecting patient selection that might have already taken place based on MRSI suggestive larger tumor extent. Pirzkall et al. (15) presented initial preliminary data on the actual impact on target definition for SRS if MRSI data was to be incorporated into the treatment planning process, showing that target definition as well as dose prescription and patient eligibility might be affected, providing the motivation for the detailed study presented here.
In this study, we examined the difference between the radiosurgical target defined by (a) conventional standards that target the Gadolinium (Gad) enhancing lesion, and (b) defined by the MRSI derived metabolic lesion. We also investigated the potential impact on SRS treatment planning if incorporating (b) into (a). In addition, we studied the follow-up MRI and MRSI exams following SRS and analyzed any new or enlarged CE as compared to the pre-SRS MRI/MRSI exams to study the spatial correspondence and assess spectroscopic changes to aid in the interpretation of new CE as due to radiation necrosis vs. persistent or recurrent tumor. Lastly, follow-up MRSI data were examined and correlated with previously reported survival data to determine possible trends of metabolic activities indicative of resistant tumor pattern.
Materials and Methods

Patient Population
We retrospectively studied 26 patients treated with Gamma Knife radiosurgery at our institution for histologically confirmed grade IV glioma according to the World Health Organization (WHO) II criteria. Twenty-five patients had glioblastoma multiforme (GBM), and one patient was diagnosed to have a gliosarcoma (GS). The patient population included 13 men and 13 women with ages ranging from 26 to 83 years (median 52 years). All patients signed consent forms approved by the Committee on Human Research at our institution.
Treatment
All 26 patients were previously treated with RT and chemotherapy. Eighteen patients underwent SRS at the time of recurrence (median 5.4 months, with a range of 2 to 8 months after RT) while eight received SRS as a boost following a course of fractionated conformal RT (performed within four weeks after RT). All patients were treated with Gamma Knife RS (Elekta Instruments, Inc., Atlanta, GA) between December 1998 and August 2001. Even though MRSI data were acquired as part of an approved study protocol for all 26 patients, the data were not shared with the treating physicians and the target volumes were defined solely based on standard MRI. After the placement of a stereotactic frame, patients underwent MRI (for treatment planning) prior to SRS, and the radiosurgical target was defined as the contrast enhancing (CE) region or the resection cavity (in all eight cases of radiosurgical boost). Target volumes ranged from 1.5 cc to 19.2 cc. The prescribed dose ranged from 12 to 26.5 Gy prescribed to the 50% isodose line, with a median marginal tumor dose of 16 Gy.
MRI/MRSI
All MRI and MRSI exams were performed on a 1.5 T Signa Echospeed clinical scanner (General Electric Medical Systems, Milwaukee, WI) equipped with a standard quadrature head coil. The MR exams were done on the day of the treatment (after placement of the stereotactic frame), while the MRSI was conducted either on the day of treatment in conjunction with the treatment planning MRI exam or within one week prior to the SRS treatment. The MRI treatment planning scans included a T2 weighted image using axial fluid-attenuated inversion recovery (FLAIR) sequence and/ or a fast spin echo (FSE) with 3 mm slice thickness, an axial T1-weighted pre-contrast 3D spoiled gradient echo (SPGR) and an axial post-contrast SPGR, both latter sequences acquired in 1.5 mm thick slices throughout the head. All images were subsequently aligned to the T1w post-Gad SPGR (reference image). The acquisition parameters used have been reported elsewhere (14, 16) .
If the MRI and MRSI exams were performed on different days, the respective MRSI data were aligned to the treatment planning image data set and dose distribution matrix. This was accomplished using an image registration technique that maximized the volume overlap and minimized the surface deviation between two masks, as described previously elsewhere (12, 17) .
The acquisition, processing, and analytical techniques for spectroscopy data have also been detailed previously (6, 16) . To summarize briefly, the spectra underwent baseline, frequency, and phase correction. The relative metabolite levels were expressed as the peak heights normalized to the standard deviation of the spectral noise from the right side of the spectrum where no peaks were present. For each voxel in the three-dimensional array, the Cho-to-NAA index (CNI) was calculated via an automated regression technique. The CNI is equal to the number of standard deviations that the Cho-to-NAA ratio of a voxel is away from the Cho-to-NAA ratio of the regression line through the population of control voxels (18). In essence, the CNI is a quantitative and continuous measure of the probability of metabolic abnormality, and a CNI value of 2.0 corresponds to the lowest value of biopsy confirmed tumor (12).
Radiosurgical Target vs. Metabolic Lesion
One of our objectives was to assess the difference in SRS target volumes as defined by MRI alone and that resulting from the incorporation of additional information from metabolic imaging, as obtained by MRSI. On all MRI data sets, the T1 weighted contrast-enhanced regions and the resection cavity for the eight cases of boost treatments were manually contoured by the same person in order to avoid inter-user variability. For each voxel in the 3D-MRSI data array, the CNI was calculated and used as a quantitative measure of the probability of metabolic abnormality. Subsequently, the CNI data were interpolated to match the resolution of the T1w MRI, aligned to the treatment planning MRI and displayed as 3 D contours. Furthermore, the volumes of CE and CNI 2 were computed and compared with respect to their spatial location.
Follow-up
Follow-up MRI were available for 26/26 patients, but only 15/26 patients had follow-up MRSI. The number of MRI/ MRSI follow-ups ranged from one to six, and were performed in intervals of one to three months. The follow-up imaging data sets were aligned to the pre-SRS reference images and regions of CE were contoured on all follow-up MR data sets. The delivered SRS treatment dose maps (naturally in the same reference frame as the treatment planning MR) were superimposed on all follow-up exams, to compare both the pre-SRS and follow-up CE volumes with the treated volume (50% IDL) and the pre-SRS CNI 2 volume, in order to determine its spatial correspondence with areas of new or enlarged CE.
Follow-up MRSI metabolic data were also evaluated to assess the metabolic response pattern following SRS, and to determine if new/enlarged CE during follow-up was suggestive of necrosis, persistent, or recurrent tumor. For this purpose, a common PRESS box was created between the 1  18  13  2  15  15  3  13  10  4  12  12  5  18  16  6  19  16  7  18  15  8  12  10  9  19  18  10  18  16  11  19  19  12  16  13  13  18  18  14  14  10  15  16  12  16  18  16  17  20  18  18  18  18  19  12  12  20  16  12  21  14  10  22  12  10  23  19  19  24  19  14  25  12  10  26 18 12 pre-SRS MRSI and the follow-up MRSI to ensure evaluation of metabolic data within the same spatial extent. The mean relative levels of Cho, Cr, NAA, and LL were calculated within the radiosurgical treatment volume (50% IDL) at pre-SRS and for all subsequent follow-ups in the common PRESS using a Matlab program. The numerical values for these metabolites were then compared.
Results
Radiosurgical Target Volume and Dose Prescription
The volumes of CE and CNI2 differed for each of the 26 patients. The CE volumes ranged from 2 cc to 20 cc, with a median of 7 cc, while the CNI2 volume ranged from 2 cc to 27 cc, with a median of 13 cc. Figure 1 displays an example of a patient with recurrent GBM where the CNI 2 clearly extends beyond the CE and would have enlarged the target volume from 2.3 cc (CE alone) to 4.5 cc. Table I lists As can be seen on the left, the CNI2 (red contour) extended beyond the CE volume which was treated with SRS. On follow-up exam, the larger CE volume appeared to have outgrown from the pre-SRS CNI2 extent that remained untreated by SRS. the volumes of CE, CNI 2, and combined (CE + CNI2) as a resulting new target volume for each patient and Figure  2 depicts graphically the changes in target volume if CNI 2 was incorporated into the target definition. There were only minimal changes in the resulting radiosurgical target volume of less than 2cc in 11 patients, whereas the incorporation of CNI 2 to the CE resulted in changes of more than 2cc in 14 patients. Table II compares the original and the adjusted dose prescription for each patient calculated based on a dose volume relationship curve used at our institution. The dose prescription would have been affected towards prescribing a lower dose in 19/26 patients due to increased target volume, and the new radiosurgical volume comprised of CE and CNI 2 would have exceeded 20 cc in five patients. Those patients would have been considered ineligible for Gamma Knife RS based on our institutional policy.
The above calculations consider the CE as the gold standard for radiosurgical target definition and add the metabolically abnormal regions to it. One could also consider to treat the metabolically active regions only. In that case the CE with CNI < 2 would be disregarded and not included in the target definition. We found that the radiosurgical volume would have decreased in all patients of this study (ranging from 0.5 cc to 11.2 cc, median 2.1 cc) as displayed in Figure 3 . Reduced target volumes would have allowed the prescription of the same or an even higher dose in 8 and 14 patients, respectively.
MRSI Serial Findings
Even though all 26 patients had a median of 2 (ranging from 1 to 8) follow-up MRI exams (with intervals ranging from one to six months), only 15/26 patients had additional MRSI exams (ranging from one to six exams). Interestingly, 70% of these available follow-up exams were from patients whose CNI 2 volumes extended only slightly beyond the original CE volumes at pre-SRS MRI (median of 2 cc, range 0.8-4.2 cc), implying that patients with rather extensive metabolic disease suggested by a larger CNI 2 volume that extended beyond CE (median of 8 cc, range 1.6-15.2 cc) did not come back for follow-up. This is also reflected in the worse median survival of 10.2 months for the latter patients compared to median 15.7 months for the patients with more lengthy follow-up.
Visual inspection of CE in the 15 patients with MRI/MRSI follow-ups revealed either stable (eleven) or increased CE in four patients. MRSI follow-up studies showed in the patients with stable CE, a decrease in Choline peaks (median of 3.4 at 3 -6 month follow-up as compared to a median of 11.0 at the pre-SRS exam), stable Creatine and increased NAA, with the CNI2 volume noticeably decreased as compared to pre-SRS MRSI data (< 1 cc versus median 4.6 cc, respectively).
Early increased CE during follow-up as seen in 4/15 patients was associated with stable or worsened metabolic pattern. This was characterized by stable or slight increase of the Choline peak (median 12.7, ranging from 2.69 to 16.44), and an increase in the CNI 2 volume (median of 14.2 cc, range 8.2 to 17.6) compared to median Choline levels of 11.0 and CNI 2 volume of 12.4 cc at pre-SRS, suggesting possible recurrence. These patients had a shorter survival (median of 9.1 months, ranging from 3.5 to 11.8 months) as compared to patients with diminished Choline peaks (median of 14.9 months, ranging from 10.9 to 33 months). A statistical analysis of these data was not performed due to the small number of data points. Figure 4 shows the serial metabolite changes for all 15 patients. The mean Cho levels increased during follow-up in three patients, with new (one) and enlarged (two) CE. It is interesting to note that the Cho levels did not decrease after SRS in these patients. An examination of the SRS treated volume suggested that the pre-SRS CNI 2 volumes expanded significantly beyond the CE volume (4.2 cc to 6.5 cc) in these patients with increase CE.
With respect to CE changes, the Cho levels appeared to be slightly elevated as compared to pre-SRS (12.5 vs. 10.9) in patients with increased CE; whereas, median Cho levels did not deviate much from the pre-SRS median Cho (9.4 vs. 9.6) for patients with stable or decreased CE. The survival times for patients with stable or decreased CE did not seem to differ significantly (median 10.2 months vs. 11 months, respectively). With respect to metabolic change, patients with stable/increased Cho developed increased CE volumes (median of 20.4 cc vs. 14.7 cc). For patients with decreased Cho, the CE volumes did not seem to differ relative to pre-SRS (median 12.6 vs. 13.5 cc). These patients appeared to have a slightly longer survival time than patients with increased Cho levels (median 13.6 months vs. 12.2 months).
Figure 5(a) shows a patient whose CNI 2 extended outside the pre-SRS CE and remained untreated at the time of Gamma Knife RS; Figure 5 (b) shows the new CE at six months post SRS which corresponded spatially to the volume of CNI 2 that remained untreated.
Discussion
While studies have shown that stereotactic radiosurgery could provide modest efficacy with acceptable toxicity in patients with recurrent gliomas, these studies were not able to demonstrate a significant survival benefit (19, 20) . However, it also has to be recognized that no proper prospective trial has been conducted to date to study a potential survival benefit, leaving the role of radiosurgery in the treatment of patients with recurrent glioma undefined.
One possible explanation for the only modest results to date could be due to insufficient delineation of tumor extent and respective target definition; another could be the amount of radiation dose delivered. Our group had already demonstrated that metabolically active tumor clearly extends beyond the T1w CE region traditionally used for SRS target definition in a significant proportion of patients (8, 10, 13, 14) , and that failure to include such metabolically active volume seemed to lead to shorter survival (11, 14) . The current study extended these previous analyses and quantified the degree of actual volumetric difference by incorporating the volume of metabolic abnormality, specifically the CNI 2. We could show that the conventional target definition based on CE alone would leave metabolically active regions of considerable size untreated in the vast majority of patients while the CE itself that is treated resembles in part metabolically silent, i.e., necrotic, regions. However, whether and how to incorporate the metabolic information into the radiosurgical target definition are still topics of discussion given the fact that a lower prescription dose would most oftentimes have to be chosen due to the resulting increase in the target volumes and the confining dose-volume limitations, which in turn could possibly reduce the effectiveness of the SRS altogether (pending the actual clinical implementation, tumor control-and toxicity-dose relationships remain unestablished). A possible strategy could be to exclude the necrotic region within the CE for treatment (i.e., effectively decrease the total treatment volume) and target only the metabolically active regions (≥ CNI 2). This might be shown to be a better approach leading to an acceptable treatment volume and still allow for delivery of an effective dose. We are planning to answer this question through currently ongoing image-guided biopsies in recurrent gliomas that specifically target contrast enhancing and non-contrast enhancing regions depending on their metabolic characteristics. Subsequently, we are planning to launch a phase I/II Gamma Knife SRS treatment protocol at our institution for recurrent gliomas that incorporates MRSI for target definition.
Another difficulty in the management of recurrent gliomas is to assess treatment response. The current practice of determining whether the tumor has responded to SRS is to compare the pre-treatment and follow-up MRI exams and to determine the degree of contrast enhancing changes, whereby an increase of more than 25% associated with clinical deterioration is typically interpreted as possible cancer recurrence. However, as has been stated before by other investigators, both recurrent brain tumor and radiation induced necrosis appear within the irradiated volume as contrast-enhancing, expansive brain lesions surrounded by edema (21). We analyzed MRSI serial changes available in 15 patients in order to study radiation response. Following recommendations from previous studies, we calculated the average metabolite levels in the follow-up MRSI and evaluated based on those levels whether the new/ residual CE volumes could be suggestive of radiation necrosis or tumor recurrence or persistence (21, 22) . We found particularly Cho levels to be a possible biomarker of therapeutic response. Stable or increasing levels of Cho were associated with higher likelihood of increased CE and slightly shorter survival. Our findings are consistent with other studies that report unchanged or elevated levels of Cho to be typical for recurrent tumor, while a pervasive lack of overall metabolite signals, or increased LL peak height accompanied by low Cho levels were indicative of radiation induced necrosis (21). Kamada et al. (22) investigated metabolite ratios to distinguish between necrosis and recurrence. It was shown by correlating with histological diagnosis that a higher Lac/Cr ratio and a lower Cho/Cr ratio were present in radiation necrosis as compared to recurrent gliomas. In the present study, only the peak heights of the metabolites were analyzed.
Finally, spatial correspondence of areas of new/increased CE within pre-SRS CNI2 extent as seen in 70% of patients supports the concept of including these regions in the target volume for radiosurgery. Whether such approach would increase local control and prolong survival remains to be determined by future studies using this methodology.
Conclusion
The results of this study demonstrate the potential impact of integrating the spectroscopic abnormality (CNI 2) along with the conventional MRI abnormality (CE) for the target definition for radiosurgery. Our findings suggest that metabolic disease as measured by CNI 2 extends beyond the CE in the majority of cases with recurrent high-grade glioma. Thus, treating a target defined solely by the CE would miss metabolically active tumor that resides beyond the CE. By incorporating CNI2, the radiosurgical target volume could change substantially for some patients, could result in a lower SRS prescription dose, and render some patients ineligible for SRS radiosurgery based on our institutional policy.
For patients whose CNI2 volume extended substantially beyond the SRS treatment volumes, it was more likely that the follow-up CE volume was due to recurrence, as suggested by their increased Cho levels and shorter survival time, as compared to patients whose CNI 2 volume closely correlated with the SRS treatment volume. These latter patients demonstrated decreased Cho levels during follow-up exams, which can be interpreted as a measure of treatment effect. On the contrary, our preliminary data suggest that an increase in Cho over time could be interpreted as an early indicator for recurrent tumor, warranting more aggressive treatment for the patient. Therefore, follow-up with MRSI seems to be a promising tool to assist in the interpretation of CE changes, and it could be potentially beneficial to use serial MRSI information to closely monitor treatment response. 
